Medicare price negotiation and pharmaceutical innovation following the inflation reduction act
Abstract The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for
some medicines with high Medicare spending. Using historical data from public and …
some medicines with high Medicare spending. Using historical data from public and …
How do copayment coupons affect branded drug prices and quantities purchased?
We estimate the causal effects of drug copayment coupons, which reduce consumer cost
sharing for branded prescription drugs, on net-of-rebate price and quantities sold. We show …
sharing for branded prescription drugs, on net-of-rebate price and quantities sold. We show …
[HTML][HTML] The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets
Health systems around world are increasingly adopting cost-effectiveness (CE) analysis to
inform decisions about access and reimbursement. We study how CE thresholds imposed …
inform decisions about access and reimbursement. We study how CE thresholds imposed …
Biomed Europa: after the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly
After a brief analysis of the causes underlying the failure of both governments and the
pharma industry in terms of preparedness for the COVID‐19 pandemic, and after a …
pharma industry in terms of preparedness for the COVID‐19 pandemic, and after a …
The economics of medical procedure innovation
This paper explores the economic incentives for medical procedure innovation. Using a
proprietary dataset on billing code applications for emerging medical procedures, we …
proprietary dataset on billing code applications for emerging medical procedures, we …
The contribution of price growth to pharmaceutical revenue growth in the United States: evidence from medicines sold in retail pharmacies
Context: To what extent does pharmaceutical revenue growth depend on new medicines
versus increasing prices for existing medicines? Moreover, does using list prices, as is …
versus increasing prices for existing medicines? Moreover, does using list prices, as is …
[PDF][PDF] Pharmacy benefit managers and vertical relationships in drug supply: state of current research
ZC Brot-Goldberg, C Che, BR Handel - 2022 - nber.org
Despite their importance to the supply of prescription drugs, there has been limited research
on pharmacy benefit managers (PBMs) and their vertical relationships to insurers and drug …
on pharmacy benefit managers (PBMs) and their vertical relationships to insurers and drug …
R&D and market size: Who benefits from orphan drug legislation?
Since the early 80s, incentives have been introduced to stimulate R&D for rare diseases. We
develop a theoretical model to study the impact of push and pull incentives on the intensive …
develop a theoretical model to study the impact of push and pull incentives on the intensive …
[图书][B] Why not better and cheaper?: healthcare and innovation
JB Rebitzer, RS Rebitzer - 2023 - books.google.com
An engaging account of innovation in healthcare and why the results fall short for patients
and society. The evolution of the cell phones we carry in our pockets demonstrates that …
and society. The evolution of the cell phones we carry in our pockets demonstrates that …
Improving Regulation for Innovation: Evidence from China's Pharmaceutical Industry
This study investigates how enhanced regulation can promote innovation, focusing on the
impacts of a significant regulatory reform in China's pharmaceutical sector implemented in …
impacts of a significant regulatory reform in China's pharmaceutical sector implemented in …